One-stop-shop for artificial intelligence applications launched.
CHICAGO - Finding and purchasing AI imaging applications just got a bit easier.
IBM Watson Health Imaging announced the launch of its Imaging AI Marketplace at this year’s annual meeting of the Radiological Society of North America in Chicago. The single-source solution marketplace is designed to help streamline the process of locating, buying, deploying, and managing the ever-growing options for AI Imaging applications. The one-stop-shop experience simplifies a process that can be complex and resource-draining.
As a carefully-controlled database of AI applications, the IBM Imaging AI Marketplace only includes solutions that have been cleared by the U.S. Food & Drug Administration, as well as AI solutions developed by Watson Health. This vetted catalog offers solutions for a wide range of specialties and modalities to meet customer needs.
In addition to this extensive collection of applications, the Imaging AI Marketplace also helps customers deploy AI imaging applications into their existing clinical workflow, potentially minimizing disruptions to physician productivity, and maximizing patient care.
Customers can access the Imaging AI Marketplace via IBM Watson Health’s iConnect™ Enterprise Archive.
To date, IBM Watson Health Imaging has several vendor partners for its Imaging AI Marketplace. So far, the company has partnered with Circle Cardiovascular Imaging, DiA Imaging Analysis Ltd., MaxQAI, Quantib BV, VIDA LungPrint.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Can CT-Based Deep Learning Bolster Prognostic Assessments of Ground-Glass Nodules?
June 19th 2025Emerging research shows that a multiple time-series deep learning model assessment of CT images provides 20 percent higher sensitivity than a delta radiomic model and 56 percent higher sensitivity than a clinical model for prognostic evaluation of ground-glass nodules.
FDA Clears Ultrasound AI Detection for Pleural Effusion and Consolidation
June 18th 2025The 14th FDA-cleared AI software embedded in the Exo Iris ultrasound device reportedly enables automated detection of key pulmonary findings that may facilitate detection of pneumonia and tuberculosis in seconds.